Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial

Lancet

Volumn 364, Issue 9444, 2004, Pages 1489-1496

  Filippi, Massimo ^a,e   Rovaris, Marco ^a   Inglese, Matilde ^a   Barkhof, Frederik ^b   Stefano, Nicola De ^c   Smith, Steve ^d   Comi, Prof Giancarlo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Department of Neurology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PLACEBO;

ADULT; ARTICLE; AUTOANALYSIS; BRAIN RADIOGRAPHY; BRAIN SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; TREATMENT OUTCOME;

EID: 6944246720     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17271-1     Document Type: Article

References (43)

1. Rovaris M, Filippi M. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Curr Opin Neurol. 12:1999;337-344
2. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 44:1994;635-641
3. O'Riordan JI, Thompson AJ, Kingsley DPE, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain. 121:1998;495-503
4. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 346:2002;158-164
5. Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 125:2002;1676-1695
6. Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Brain atrophy in relapsing-remitting multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler. 6:2000;365-372
7. Kalkers NF, Bergers E, Casteljins JA, et al. Optimizing the association between disability and biological markers in MS. Neurology. 57:2001;1253-1258
8. Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 70:2001;773-780
9. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 59:2002;1412-1420
10. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 343:2000;898-904
11. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 357:2001;1576-1582
12. Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology. 54:2000;1689-1691
13. Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry. 73:2002;141-147
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452
15. Sipe JC, Knobler RL, Braheny S, Rice GP, Panitch HS, Oldstone MB. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology. 34:1984;1368-1372
16. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psychiatry. 54:1991;683-738
17. Rovaris M, Filippi M, Calori G, et al. Intra-observer reproducibility in measuring new MR putative markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. J Neurol. 244:1997;266-270
18. Smith SM, De Stefano N, Jenkinson M, Matthews P. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 25:2001;466-475
19. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust and automated longitudinal and cross-sectional brain change analysis. NeuroImage. 17:2002;479-489
20. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging. 16:1997;623-629
21. Trapp BD, Peterson J, Ransohoff, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 338:1998;278-285
22. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 51:1998;682-689
23. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L and the Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999; 53: 1698-704.
24. Jones CK, Riddehough A, Li DKB, Zhao G, Paty DW, and the PRISMS Study Group. MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS trial. Neurology 2001; 56 (suppl 3): 379 (abstr).
25. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 352:1998;1498-1504
26. Martino G, Adorini L, Rieckann P, Hillert J, Comi G, Filippi M. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol. 1:2002;499-509
27. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 126:2003;433-437
28. Kalkers NF, Ameziane N, Boost JCJ, Minneboo A, Polman CH, Barkhof F. Longitudinal brain volume measurement in multiple sclerosis. Rate of brain atrophy is independent of the disease subtype. Arch Neurol. 59:2002;1572-1576
29. Rovaris M, Iannucci G, Cercignani M, et al. Age-related changes of conventional, magnetization transfer and diffusion tensor MRI findings: a study with whole brain tissue histogram analysis. Radiology. 227:2003;731-738
30. Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol. 21:2000;1034-1038
31. Traboulsee A, Dehmeshki J, Brex PA, et al. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology. 59:2002;126-128
32. Rao AB, Richert N, Howard T, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNβ-1b. Neurology. 59:2002;688-694
33. Saindane AM, Ge Y, Udupa JK, Babb JS, Mannon LJ, Grossman RI. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS. Neurology. 55:2000;61-65
34. Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol. 58:2001;57-60
35. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M, and the European/Canadian Glatiramer Acetate Study Group. Short term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001; 124: 1803-12.
36. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 343:2000;938-952
37. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 46:1999;296-304
38. Mastronardo G, Rocca MA, Iannucci G, Pereira C, Filippi M. A longitudinal study of the presymptomatic phase in a patient with clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 20:1999;1268-1272
39. Gasperini C, Paolillo A, Rovaris M, et al. A comparison of the sensitivity of MRI after double and triple dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magn Reson Imaging. 18:2000;761-763
40. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci. 41:1979;81-89
41. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist. 5:1999;48-57
42. Kaplan MR, Meyer-Franke A, Lambert S, et al. Induction of sodium channel clustering by oligodendrocytes. Nature. 386:1997;724-728
43. Pfrieger FW, Barres BA. Synaptic efficacy enhanced by glial cells in vitro. Science. 277:1997;1684-1687